Corpus ID: 34792839

CYP2D6 Metabolizer Phenotypes in Patients Undergoing ECT After Antidepressant Therapy

@inproceedings{Mirzakhani2016CYP2D6MP,
  title={CYP2D6 Metabolizer Phenotypes in Patients Undergoing ECT After Antidepressant Therapy},
  author={H. Mirzakhani and Juli{\"e}t van Dormolen and K. Weide and H. Guchelaar and M. V. Noorden},
  year={2016}
}
  • H. Mirzakhani, Juliët van Dormolen, +2 authors M. V. Noorden
  • Published 2016
    • Introduction Major depressive disorder (MDD) and bipolar disorder (BD) are common mental disorders. According to present guidelines, the effective antidepressant for treatment of MDD and BD for each individual patient is identified through trial and error switching in sequential treatments. A substantial proportion of depressive patients do not benefit from treatment due to ineffectiveness of medication therapy or incurring serious side effects. CYP2D6 variants are associated with metabolic… CONTINUE READING
    openaccess.leidenuniv.nl
    1 Citations

    Tables from this paper

    Tables

    One Citation
    Citation Type

    Citation Type

    The role of clinical pharmacology and pharmacogenetics in electroconvulsive therapy : from safety to efficacy

    References

    SHOWING 1-10 OF 68 REFERENCES
    Pharmacogenetics of antidepressant medication intolerance.
    • 252
    • PDF
    The role of pharmacogenetics in the treatment of depression and anxiety disorders
    • 66
    Patients with difficult-to-treat depression do not exhibit an increased frequency of CYP2D6 allele duplication.
    • 6
    Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
    • 657
    • PDF
    No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline
    • 55
    [Retrospective assessment of the antidepressants tolerance in the group of patients with diagnosis of depression and different CYP2D6 genotype].
    • 3
    Clinical features of bipolar depression versus major depressive disorder in large multicenter trials.
    • 175
    Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients
    • 76
    Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study
    • 146
    CYP2D6 Genotype: Impact on Adverse Effects and Nonresponse During Treatment with Antidepressants—a Pilot Study
    • 187